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Abstract 
We report a case of hepatocellular carcinoma (HCC) with chronic hepatitis C virus 
infection successfully treated with percutaneous radiofrequency ablation (RFA) under 
live four-dimensional (4D) echo guidance. A 65-year-old Japanese man had a HCC nodule 
in the liver S5 region 2.0 cm in diameter. We performed real-time 4D ultrasonography 
during RFA therapy with a LeVeen needle electrode. The echo guidance facilitated an 
accurate approach for the needle puncture. The guidance was also useful for confirming 
whether an adequate safety margin for the nodule had been obtained. Thus real-time 
4D ultrasonography echo technique appears to provide safe guidance of RFA needles 
via accurate targeting of HCC nodules, thereby allowing real-time visualization when 
combined with echo contrast. Furthermore the position of the needle in a still image was 
confirmed in every area using a multiview procedure. 
Introduction 
Hepatocellular carcinoma (HCC) is increasing worldwide, including the United States 
and Europe, and is thus a global problem [1, 2]. Patients with chronic liver disease related 
to hepatitis B or C virus constitute a high-risk group for the development of HCC [3]. 
Surgical resection for HCC has a limited role because of underlying cirrhosis or the 
presence of multiple HCC lesions. Accordingly various nonsurgical therapies have been  
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attempted. Among them, percutaneous therapies such as percutaneous ethanol injection, 
microwave coagulation and radiofrequency ablation (RFA) have been widely applied 
[4, 5]. RFA may be the most promising of these treatment strategies. Studies evaluating 
the tumor vascularity of HCC have been conducted extensively using various imaging 
modalities.  
The recent advances in ultrasonography (US) devices in conjunction with better 
contrast agents have greatly improved sensitivity in evaluating the hemodynamics of liver 
tumors based on the availability of real-time gray-scale harmonic US imaging [6]. Since 
we are expected to ablate the tumor nodule with an adequate safety margin, a more 
accurate procedure and positioning of the inserted needle during RFA employing more 
advanced devices is clearly desirable. Herein we report a case with HCC successfully 
treated with percutaneous RFA under real-time 4D US guidance.  
Case Report 
A 65-year-old Japanese man was referred to our outpatient clinic in February 2008 for treatment of a 
hepatic tumor. He had no remarkable past medical history other than chronic hepatitis C which had 
been followed at another outpatient clinic since 1999. Slightly elevated serum prothrombin induced by 
low vitamin K absence-II (PIVKA-II) levels had been noted and a hepatic tumor was detected on 
abdominal CT at a periodic examination in February 2008. He was admitted to our gastrointestinal 
ward in February 2008. On admission, his physical examination findings were unremarkable; neither 
the liver nor the spleen was palpable. There was no jaundice, ascites, peripheral edema or other sign of 
chronic liver disease. Laboratory test results included a white blood cell count of 4,900/μl, hemoglobin 
of 14.4 g/dl, and a platelet count of 111,000/μl. Liver biochemistry tests showed normal serum 
transaminases level (aspartate aminotransferase 46 IU/l and alanine aminotransferase 35 IU/l) and 
normal total bilirubin (0.8 mg/dl). Other laboratory tests results were within normal ranges as well 
(table 1). The PIVKA-II level was 1,570 mAU/ml (normal <40 mAU/ml), and α-fetoprotein (AFP) was 
within normal range (5.0 ng/ml). He was seropositive for anti-hepatitis C virus by a second-generation 
enzyme immunoassay (Dainabot, Tokyo, Japan) and the presence of serum hepatitis C virus RNA was 
confirmed by Amplicore (Roche Diagnostic Inc., Tokyo, Japan). 
Fundamental B-mode US scan showed the presence of a low-echoic lesion in the S5 area 2.0 cm in 
diameter. On dynamic CT, the nodule showed tumor staining in the early arterial phase and washout 
density in the postvascular phase. We performed contrast-enhanced US with a PVT-382MV probe from 
APLIO XG (Toshiba Medical Systems, Otawa, Japan). The vascularity of the HCC lesion was assessed 
by microflow imaging using 0.5 ml of sonazoid (Daiichi-Sankyo, Tokyo, Japan) [7]. The US imaging 
was focused at the base of the target tumor. The images were taken in the early vascular phase from 10 s 
until 40 s after injection; tumor vessel and staining were clearly observed (fig. 1). The CT and US 
findings indicated that the patient had HCC. Since he refused angiography or surgery, RFA was selected 
as therapy.  
RFA was conducted for 12 min under a percutaneous approach using an expandable LeVeen needle 
with a hook 3.5 cm in diameter (Boston Scientific, USA). During and after the procedure, real-time 4D 
US was applied for accurate positioning of the needle and for confirmation of adequate ablation with a 
sufficient safety margin. We also confirmed the position of the needle using the multiview detector with 
which this model is equipped, and the solid mode which allows depiction of lesions in units of several 
millimeters as one area as on a CT scan. The area of the treated portion included the gallbladder, and 
both needle position and safety margin from the gallbladder were confirmed. It was possible to observe 
the tumor from multiple directions including lateral superior and inferior portions (fig. 2). Dynamic CT 
scan performed 3 days after RFA showed no tumor staining with a low-density area corresponding to 
the tumor-affected part of the liver in the early arterial phase. Dynamic CT also indicated an adequate 
safety margin for the nodule. After RFA treatment, contrast-enhanced US was performed and the site of 
the enhanced tumor was visualized as a defect (fig. 3).  
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Discussion 
This is the first report demonstrating that contrast-enhanced 4D real-time US imaging 
can safely and accurately guide needle puncture during RFA therapy in a patient with 
HCC.  
US is the most commonly used imaging method for diagnosing hepatic tumors. The 
improvement of US devices with contrast agents appears to contribute to increased 
sensitivity and accuracy in evaluating the hemodynamics of hepatic tumors, e.g. the 
development of a new method with microflow imaging. This study demonstrated the 
possibility of easily assessing intratumoral blood flow dynamics in patients with hepatic 
tumors [5, 6]. In addition, with the use of the contrast agent sonazoid, small vessels and 
low perfusion could be depicted in real time. Since the microflow imaging used herein 
allowed alteration of the images and serial measurements of signals in addition to the 
information provided by contrast agent use, suppressing the signals from surrounding 
tissues (liver parenchyma), it was possible to easily image the structures of fine, complex 
blood vessels. Also, visualization using this contrast agent can be repeated many times 
because it accumulates and remains in the liver for a very long time. A newly introduced 
4D US, incorporating dynamic real-time 3D US with a continuous volume data set 
acquisition capacity, provided improved visualization and more valuable information on 
the mutual relationship between ablation and hepatic mass [8, 9]. 
The probe which we used herein was a microconvex type probe which is smaller than 
the one we reported previously. However the tumor depiction ability was good, though 
since we could not perform the desired imaging with this probe, we used other probes for 
puncture under real-time 4D biopsy with this probe. For the trace, we observed the needle 
and anticipate its future use for guiding accurate puncture. Despite improved US devices, 
we occasionally experience cases in whom accurate positioning of the RFA needle is 
difficult because the nodules are indistinct. There are disadvantages to using 4D US, e.g. 
the fact that current 4D ultrasonic transducers are bulkier and heavier than conventional 
2D transducers, resulting in some difficulty in handling the probe. Moreover, the 
mechanical sweeping motion of the 4D transducer generates a mechanical vibration 
during the RFA procedure. 
We used a real-time 4D US device for RFA therapy in the present study and confirmed 
that the needle was inserted accurately into the center of the target tumor. The tumor 
was ablated with an adequate safety margin. We easily and quickly obtained useful 
information regarding positioning of the needle. The device is advantageous in terms of 
excellent distinction between the target and surrounding tissues with rapid construction 
of 4D images and no vibration of the probe. Since this device can depict the tumor in all 
sections, it is possible to confirm the 3D positional relationships among the target, needle 
and adjacent organs such as large blood vessels, gallbladder and diaphragm. This will 
allow the RFA procedure to be performed more safely. 
The technique described herein, using a real-time 4D US device, has the limitation 
that the probe lacks guidance for the puncture. Thus it can serve as a diagnostic but 
not as a therapeutic tool. It would be optimal to have the puncture guidance along 
with development of the corresponding contrast agents. Since we can calculate the 
pretreatment tumor volume, the therapeutic effect may be evaluated by calculating the 
posttreatment volume of the nonenhanced area.  
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Table 1. Laboratory data on admission 
Chemistry 
TP 7.3  g/dl 
Alb 3.9  g/dl 
T-Bil 0.8  mg/dl 
AST 46  IU/l 
ALT 35  IU/l 
ALP 187  IU/l 
γ-GTP 32  IU/l 
LDH 181  IU/l 
Na 141  mEq/l 
K 3.8  mEq/l 
Cl 105  mEq/l 
BUN 12.2  mg/dl 
Cre 0.9  mg/dl 
CBC 
WBC 4,900/μl 
RBC 408,000/μl 
Hgb 14.4  g/dl 
Hct 43.9% 
MCV 107.6  fl 
Plt 111,000/μl 
Coagulation 
APTT 30.6  s 
PT-T 13.7  s 
PT% 87% 
PT-INR 1.10 
Tumor marker 
AFP 5.0  ng/ml 
PIVKA-II 1,570  mAU/ml 
Serum antibodies 
HCV-Ab positive 
HBs-As negative 
HBs-Ab negative 
 
 
 
  
Case Rep Gastroenterol 2011;5:82–87 
DOI: 10.1159/000321721 
Published online: 
February 1, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
86
 
Fig. 1. On contrast-enhanced US, 3 cm in diameter tumor staining can be seen in the liver S5 area in 
the early arterial phase. 
 
 
 
Fig. 2. On 4D mode in US, needle puncture during the RFA procedure and insertion into the center of 
the tumor nodule were confirmed. We also confirmed expansion of the LeVeen needle from the lower 
portion of the tumor. From another perspective, there was clearly a sufficient distance from the 
gallbadder and the needle was shown to be fully deployed. 
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Fig. 3. After treatment, contrast-enhanced US was performed and the site of the enhanced tumor was 
visualized as a defect. 
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